Allogene Therapeutics Announces Participation in November Investor Conferences

Rhea-AI Summary

Allogene Therapeutics, Inc. will participate in two investor conferences in November. The first conference is TD Cowen's 7th Annual Fall Oncology Innovation Summit on November 3rd, and the second is Jefferies London Healthcare Conference on November 15th. Webcasts of the conferences will be available on the company's website, and replays will be accessible for 30 days.

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in two upcoming investor conferences in November.

TD Cowen’s 7th Annual Fall Oncology Innovation Summit
Friday, November 3, 2023
8:30AM PT/11:30AM ET

Jefferies London Healthcare Conference
November 15, 2023
4:30AM PT/7:30AM ET/1:30PM GMT

Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on X (formerly Twitter) and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should,” “designed to” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Allogene’s ability to deliver readily available off-the-shelf cell therapy on-demand, more reliably, and at greater scale to more patients; and the therapeutic effects of Allogene’s product candidates including their ability to treat cancers at various stages. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to: our product candidates are based on novel technologies, which makes it difficult to predict the time and cost of product candidate development and the likelihood of obtaining regulatory approval; the FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our CAR T cell product candidates; and our clinical trials may fail to demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factor” Heading in its Form 10-Q filed for the quarter ended June 30, 2023. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:
Christine Cassiano
Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com

FAQ

When will Allogene Therapeutics participate in investor conferences?

Allogene Therapeutics will participate in two investor conferences in November.

What is the first conference Allogene Therapeutics will attend?

The first conference Allogene Therapeutics will attend is TD Cowen's 7th Annual Fall Oncology Innovation Summit on November 3rd.

What is the second conference Allogene Therapeutics will attend?

The second conference Allogene Therapeutics will attend is Jefferies London Healthcare Conference on November 15th.

Where can I find webcasts of the conferences?

Webcasts of the conferences can be found on Allogene Therapeutics' website under the Investors tab in the News and Events section.

How long will the replays of the webcasts be available?

Replays of the webcasts will be available on Allogene Therapeutics' website for approximately 30 days.